Skip to main content

Table 5 Adverse eventsone day after ERCP

From: Comparison of propofol-nalbuphine and propofol-fentanyl sedation for patients undergoing endoscopic retrograde cholangiopancreatography: a double-blind, randomized controlled trial

 

GroupPF(N = 199)

GroupPN(N = 201)

P value

95% CI

Odds ratio

Total adverse events(n)% a

49(23.62%)

52(25.88%)

0.38

0.77–1.22

0.94

Nausea(n)% a

20 (10.05%)

18 (8.96%)

0.35

0.78–1.47

1.14

Vomiting(n)% a

11 (5.53%)

11 (5.47%)

0.49

0.65–1.55

1.01

Pruritus(n)%

0

0

NS

  

Aspiration pneumonia(n)%

0

0

NS

  

Cough(n)%

0

0

NS

  

Polypnea and dyspnoea(n)% a

1 (0.50%)

1 (0.50%)

0.50

0.25–4.03

1.01

Abdominal pain(n)% a

15 (7.54%)

16 (7.96%)

0.44

0.67–1.42

0.94

VAS score(points) b

0.16 ± 0.75

0.13 ± 0.62

0.11

-0.03–0.15

––-

Fever(n)% a

2 (1.01%)

6 (2.99%)

0.08

0.15–1.66

0.33

Medical treatment for adverse events(n)% a

17 (8.54%)

18 (8.96%)

0.44

0.8–1.39

0.95

  1. Values are presented as the frequency (%),Chi-squared testa.Values are presented as the mean ± SD. One-sample t test b.VAS score visual analogue score, NA not available